Opiant Pharmaceuticals (Opiant Pharmaceuticals) Debt-to-Equity : 0.81 (As of Sep. 2022)

View and export this data going back to 2007. Start your Free Trial

What is Opiant Pharmaceuticals Debt-to-Equity?

Opiant Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2022 was $2.11 Mil. Opiant Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2022 was $14.41 Mil. Opiant Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Sep. 2022 was $20.50 Mil. Opiant Pharmaceuticals's debt to equity for the quarter that ended in Sep. 2022 was 0.81.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Opiant Pharmaceuticals's Debt-to-Equity or its related term are showing as below:

OPNT' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.43 Med: 0.01 Max: 0.81
Current: 0.81

During the past 13 years, the highest Debt-to-Equity Ratio of Opiant Pharmaceuticals was 0.81. The lowest was -0.43. And the median was 0.01.

OPNT's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.15 vs OPNT: 0.81

Opiant Pharmaceuticals Debt-to-Equity Historical Data

The historical data trend for Opiant Pharmaceuticals's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Opiant Pharmaceuticals Debt-to-Equity Chart

Opiant Pharmaceuticals Annual Data

Trend

Jul12

Jul13

Jul14

Jul15

Jul16

Jul17

Dec18

Dec19

Dec20

Dec21

Debt-to-Equity

Get a 7-Day Free Trial

0.02

0.54

0.37

Opiant Pharmaceuticals Quarterly Data
	Oct17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Debt-to-Equity	Get a 7-Day Free Trial															0.47	0.37	0.37	0.49	0.81

Competitive Comparison of Opiant Pharmaceuticals's Debt-to-Equity

For the Biotechnology subindustry, Opiant Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Opiant Pharmaceuticals's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Opiant Pharmaceuticals's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Opiant Pharmaceuticals's Debt-to-Equity falls into.

Opiant Pharmaceuticals Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Opiant Pharmaceuticals's Debt to Equity Ratio for the fiscal year that ended in Dec. 2021 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.338	+	16.742)	/	46.84
	=	0.36

Opiant Pharmaceuticals's Debt to Equity Ratio for the quarter that ended in Sep. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2.106	+	14.408)	/	20.502
	=	0.81

Opiant Pharmaceuticals (NAS:OPNT) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Opiant Pharmaceuticals Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Opiant Pharmaceuticals's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Opiant Pharmaceuticals (Opiant Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Opiant Pharmaceuticals Inc (NAS:OPNT) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

233 Wilshire Boulevard, Suite 280, Santa Monica, CA, USA, 90401

Website

https://www.opiant.com

Opiant Pharmaceuticals Inc is a specialty pharmaceutical company operating in the US. It develops pharmacological treatments for substance use, addictive and eating disorders. The company has developed NARCAN, a Nasal Spray for treatment to reverse opioid overdoses. The company's pipeline includes medicines in development for Opioid Overdose Reversal (OOR), Alcohol Use Disorder (AUD), Opioid Use Disorder (OUD) and Acute Cannabinoid Overdose (ACO). The majority of the revenue is generated in the form of Royalty and licensing.

Executives

David D O'toole	officer: Chief Financial Officer	1640 MARENGO STREET, LOS ANGELES CA 90033
Ellison Mark Jason Heath	other: UK Managing Director	C/O OPIANT PHARMACEUTICALS, INC., 201 SANTA MONICA BLVD., SUITE 500, SANTA MONICA CA 90401
Roger Crystal	director, 10 percent owner, officer: Chief Executive Officer	445 PARK AVE, 10TH FL., NEW YORK NY 10022
Phil Skolnick	officer: Chief Scientific Officer	C/O DOV PHARMACEUTICAL, INC., 433 HACKENSACK AVENUE, HACKENSACK NJ 07601
Brian Gorman	other: General Counsel	233 WILSHIRE BLVD, SUITE 280, SANTA MONICA CA 90401
Matthew R. Ruth	officer: Chief Commercial Officer	233 WILSHIRE BLVD., SUITE 280, SANTA MONICA CA 90401
Michael Sinclair	director, 10 percent owner, officer: Executive Chairman	86 GLOUCESTER PLACE, LONDON XX W1U6HP
Craig A Collard	director	C/O CORNERSTONE THERAPEUTICS INC., 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
Ann L. Macdougall	director	C/O OPIANT PHARMACEUTICALS, INC., 401 WILSHIRE BOULEVARD, 12TH FLOOR, SANTA MONICA CA 90401
Thomas T. Thomas	director	C/O OPIANT PHARMACEUTICALS, INC., 401 WILSHIRE BOULEVARD, 12TH FLOOR, SANTA MONICA CA 90401
Masuoka K. Lorianne	director	C/O NEKTAR THERAPEUTICS, 201 INDUSTRIAL ROAD, SAN CARLOS CA 94070
Gabrielle Alison Silver	director	C/O OPIANT PHARMACEUTICALS, INC., 401 WILSHIRE BOULEVARD, 12TH FLOOR, SANTA MONICA CA 90401
Rahsaan Thompson	other: General Counsel	233 WILSHIRE BOULEVARD, SUITE 280, SANTA MONICA CA 90401
Aziz Mottiwala	officer: Chief Commercial Officer	233 WILSHIRE BOULEVARD, SUITE 280, SANTA MONICA CA 90401
Richard J Daly	director	355 ALHAMBRA CIRCLE, SUITE 1500, CORAL GABLES FL 33134